These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22706853)

  • 1. The long and winding regulatory road for laboratory-developed tests.
    Weiss RL
    Am J Clin Pathol; 2012 Jul; 138(1):20-6. PubMed ID: 22706853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. College of american pathologists proposal for the oversight of laboratory-developed tests.
    Vance GH
    Arch Pathol Lab Med; 2011 Nov; 135(11):1432-5. PubMed ID: 22032569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Satisfying regulatory and accreditation requirements for quality control.
    Ehrmeyer SS
    Clin Lab Med; 2013 Mar; 33(1):27-40. PubMed ID: 23331727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ensuring quality in genomic medicine: amid the rise in complex laboratory-developed tests, regulatory officials are seeking the right balance on quality assurance.
    Nelson B
    Cancer Cytopathol; 2014 Dec; 122(12):855-6. PubMed ID: 25510938
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulatory compliance for point-of-care testing: 2009 United States perspective.
    Ehrmeyer SS; Laessig RH
    Clin Lab Med; 2009 Sep; 29(3):463-78. PubMed ID: 19840680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory-Developed Tests: A Legislative and Regulatory Review.
    Genzen JR; Mohlman JS; Lynch JL; Squires MW; Weiss RL
    Clin Chem; 2017 Oct; 63(10):1575-1584. PubMed ID: 28687634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives on quality control, risk management, and analytical quality management.
    Westgard JO
    Clin Lab Med; 2013 Mar; 33(1):1-14. PubMed ID: 23331725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the Food and Drug Administration's Jurisdiction Over Laboratory-Developed Tests and Divisions Between Food, Drug, and Cosmetic Act-Regulated and Clinical Laboratory Improvement Amendments of 1988-Regulated Activities.
    Thompson BM; Scott BI; Boiani JA
    Clin Lab Med; 2016 Sep; 36(3):575-85. PubMed ID: 27514469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicare, Medicaid and CLIA programs; extension of certain effective dates for clinical laboratory requirements and personnel requirements for cytologists--HCFA. Final rule with comment period.
    Fed Regist; 1994 Dec; 59(233):62606-9. PubMed ID: 10138980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing risk-based quality control plans: an overview of CLSI EP23-A.
    Person NB
    Clin Lab Med; 2013 Mar; 33(1):15-26. PubMed ID: 23331726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part II - preanalytical issues.
    Davis BH; Dasgupta A; Kussick S; Han JY; Estrellado A;
    Cytometry B Clin Cytom; 2013; 84(5):286-90. PubMed ID: 24022851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory testing under the microscope: the Clinical Laboratory Improvement Amendments of 1988.
    Raskin RD
    J Health Hosp Law; 1992 Feb; 25(2):33-6, 63. PubMed ID: 10171349
    [No Abstract]   [Full Text] [Related]  

  • 14. Medicare, Medicaid, and CLIA programs; extension of certain effective dates for clinical laboratory requirements under CLIA--CDC, HCFA. Final rule with comment period.
    Fed Regist; 1998 Oct; 63(198):55031-4. PubMed ID: 10185832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physician office laboratory regulation: proven strategies to meet the demands of the CLIA (Clinical Laboratory Improvement Amendments).
    Lee R
    Med Staff Couns; 1993; 7(3):11-26. PubMed ID: 10171471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA's framework for regulatory oversight of LDTs.
    Pathak B; Terry SF
    Genet Test Mol Biomarkers; 2014 Dec; 18(12):785-6. PubMed ID: 25469801
    [No Abstract]   [Full Text] [Related]  

  • 17. Facing the Inevitable: Being Prepared for Regulatory Requirements for Laboratory Developed Tests.
    D'Angelo R; Weiss R; Wolfe D; Chinnam R; Murat A; Gluesing J; Somers T
    Am J Clin Pathol; 2018 Apr; 149(6):484-498. PubMed ID: 29659675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part IV - postanalytic considerations.
    Barnett D; Louzao R; Gambell P; De J; Oldaker T; Hanson CA;
    Cytometry B Clin Cytom; 2013; 84(5):309-14. PubMed ID: 24022853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical immunohistochemistry laboratory: regulations and troubleshooting guidelines.
    Fetsch PA; Abati A
    Methods Mol Biol; 2010; 588():399-412. PubMed ID: 20012854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Clinical Laboratory Improvement Amendments of 1988.
    Health Care Financ Rev; 1989; 10(4):141-6. PubMed ID: 10313276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.